Dr. von Eschenbach enjoyed a 80 to 11 majority vote in the senate.

The Senate voted Andrew von Eschenbach, M.D., as chief of the FDA. Senators supported his nomination by a vote of 80 to 11. This decision comes after slightly over a year of Dr. von Eschenbach serving as acting head of the FDA. During that time he erased a major obstacle to his confirmation by allowing access to Plan B, the morning after pill, without a prescription.

“It is critical that the FDA again be the gold standard of drug approval,” Senator Hillary Clinton in her official statement. Commenting on Dr. von Eschenbach’s approval of Plan B, senator Clinton says adds, “it is vitally important that Dr. von Eschenbach continue to put science first.” 

Previous articleGSK Shells Out $454M for Domain Antibody Company
Next articleDNA2.0 Receives NSF Grant for Synthetic Gene Design